Baricitinib for Post-HSCT Persistent Thrombocytopenia

Sponsor
Peking University People's Hospital
Study ID
NCT07535645
Phase
PHASE1/PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Allogeneic Hematopoietic Stem Cell Transplantation
  • Persistent Thrombocytopenia

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • Baricitinib — DRUG
    Baricitinib, an orally administered, selective, reversible JAK1/2 inhibitor.

Study Details

This is a prospective, open-label phase 1b/2 clinical trial to explore the safety and efficacy profiles of baricitinib in patients with thrombopoietin-receptor-agonist-refractory persistent thrombocytopenia after allogeneic hematopoietic stem cell transplantation.

Key Dates

First listed
Apr 17, 2026
Start date
Mar 9, 2026
Status verified
Sep 2026
Primary completion
Dec 31, 2027
Completion
Sep 15, 2029

Study Design

Enrollment
28 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Baricitinib
    Group A: Open label baricitinib at 2 mg daily (Phase 1) Group B: Open label baricitinib at 4 mg daily (Phase 1) Group C: Open label baricitinib at the RP2D (Phase 2)

Primary Outcome Measure

Adverse events in the Ib part [ Time Frame: 24 weeks ]

Central Contacts

Related Studies